Investor Overview

Corporate Profile
 

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. Stereotaxis' core Epoch™ Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive™ robotic navigation system and consumables, which have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

FINANCIAL NEWS
11/22/19
Conference Focuses on Role of Digital Technology in Healthcare; David Fischel Named Panelist in Robotics Session ST. LOUIS , Nov. 22, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its
11/14/19
ST. LOUIS , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019 . “The third quarter was highlighted by successful

Copyright West LLC. Minimum 15 minutes delayed.

RECENT FILINGS

Filing date Form
10-Q
8-K
EFFECT
424B3
Receive E-mail Alerts
 
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Investor Contacts
 
Kimberly Peery
Chief Financial Officer
Stereotaxis, Inc.
investors@stereotaxis.com
(314) 678-6100
© Copyright Stereotaxis 2019